It’s no secret that probiotics are dominating the supplement market, and the consumer demand for foods and supplements that contain beneficial bacteria is increasing exponentially. In fact, the probiotics market is predicted to be worth $69.3 billion by the year 2023.
It’s surprisingly easy not to notice that you are living in a time of revolution. The technological revolution we are living through has been rumbling along for so long now, sometimes it’s hard to appreciate it or get excited. But the revolution in DNA sequencing and its effects on society are worth our attention – especially when it comes to how we characterize and identify natural products.
It's official: 2018 is going to be big. Our calendar is jam-packed with the year's hottest events in dietary supplements, foods, omega-3s, and probiotics.
We're always ready to help companies overcome barriers on the pathway to market. It doesn't matter if your product is new or existing, food or pharma, early or late in the product lifecycle, or at any stage of the supply chain - our team is here to help!
Schedule a meeting with us at one of the following events to learn how we can help you launch your product with confidence.
Making the decision to conduct a clinical trial can be daunting. Many complex steps are involved in getting a study off the ground, including designing the study, assessing risk, and determining whether a trial will achieve return on investment.
The International Probiotics Association (IPA) works with industry, government and academia to advance probiotic technology, research and product development.
Nutrasource is back again this year partnering with IPA to bring you the Probiotics Resource Center at SupplySide West 2017. Stop by the pavilion and meet up with our team and other people and companies who have an interest in the prebiotic and probiotic industry.
A comprehensive clinical testing program is essential to the success of virtually all health products. Writing in the International Probiotics Association blog, Josh Baisley, associate director of clinical trials for Nutrasource, notes that ensuring the stability of a probiotic for the duration of clinical studies is a vital aspect of analyzing the outcome.
As the probiotic segment continues to trend upward, more companies are investing in well-designed clinical trials to support efficacy.
One area that has presented substantial learning opportunities, and has helped shape the future of probiotic clinical trials, is the study of antibiotic associated diarrhea (AAD) and probiotic intake.
As the global voice of probiotics, the International Probiotics Association (IPA) has been working jointly with industry, government and academia to advance probiotic technology, research and product development.